<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110816">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732965</url>
  </required_header>
  <id_info>
    <org_study_id>HFHS Vitiligo Phototherapy</org_study_id>
    <nct_id>NCT01732965</nct_id>
  </id_info>
  <brief_title>NB-UVB and PUVA Vitiligo Study</brief_title>
  <official_title>Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if the combination of psoralen plus ultraviolet A and narrowband ultraviolet B
      is more effective than narrowband ultraviolet B alone in the treatment of vitiligo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine the quantity of repigmentation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination the degree of repigmentation measured by the VASI score (Vitiligo area Scoring Index) after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the quality of repigmentation.</measure>
    <time_frame>Study initiation, 3 months and 6 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of the color of repigmentation, pattern of repigmentation, and the cessation of spread of vitiligo after treating with the combination treatments (narrowband ultraviolet B and topical psoralen plus ultraviolet A) and compare it with narrowband ultraviolet B alone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>NB-UVB phototherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NB-UVB alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phototherapy and photochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NB-UVB and PUVA</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
    <arm_group_label>NB-UVB phototherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phototherapy and Photochemotherapy</intervention_name>
    <arm_group_label>phototherapy and photochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Vitiligo affecting more than 15% body surface area.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iltefat Hamzavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prescilia Isedeh, MD</last_name>
    <phone>313-916-6964</phone>
    <email>pisedeh1@hfhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virginia Reeder, MD</last_name>
    <phone>313-916-6964</phone>
    <email>vreeder1@hfhs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry Ford Dermatology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prescilia Isedeh, MD</last_name>
      <phone>313-916-6964</phone>
      <email>pisedeh1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Iltefat Hamzavi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 27, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Iltefat Hamzavi</investigator_full_name>
    <investigator_title>Senior Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>Phototherapy</keyword>
  <keyword>Photochemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
